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Introduction
A broad repertoire of mature effector T cells with specific,
diverse functional capabilities is generated in adaptive
immune responses. The differentiation and regulation of
these diverse effector cells have to be tightly regulated
and controlled to avoid unwanted immune responses. The
T cell antigen receptor (TCR) alone provides insufficient
signals for optimal T cell stimulation. A second co-
stimulatory signal for optimal T cell stimulation is needed.
Critical for the generation and control of functional
diversity are the costimulatory signals provided during the
antigen-specific stimulation of T cells by antigen-
presenting cells (APCs) [1]. The quality and magnitude of
an antigen-specific immune response are determined not
only by the quality of positive costimulation but also by the
integration of the absence of positive costimulatory signals
and the presence of negative costimulatory signals. CD28
and cytotoxic T lymphocyte antigen-4 (CTLA-4; CD152),
two homologous members of the immunoglobulin
superfamily, are the key receptors for this regulation via
positive and negative costimulation [2]. These receptors
and their pathways therefore provide promising
therapeutic targets for modulating immune responses.
Expression of CD28, CTLA-4 and their ligands
CD28 and CTLA-4 bind to the same ligands, CD86 (B7-2)
and CD80 (B7-1), which are expressed almost exclusively
on bone marrow-derived APCs. This restricted expression
of the ligands ensures that regulation of T-lymphocyte
responses by the T cell molecules CD28 and CTLA-4 is
exerted only by specialized, professional APCs. CD80 and
CD86 have different kinetics of expression. CD86 is
constitutively expressed on dendritic cells, macrophages,
and B cells and is further upregulated upon activation [3]
(D Gärtner and MC Brunner-Weinzierl, unpublished
observation). CD80 is absent from resting cells and is
expressed only upon activation of the APC. Because only
CD86 is expressed on the cell surface early after the
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Abstract
Chronic T cell responses, as they occur in rheumatoid arthritis, are complex and are likely to involve
many mechanisms. There is a growing body of evidence that, in concert with the T cell antigen
receptor signal, CD28 and cytotoxic T-lymphocyte antigen-4 (CTLA-4; CD152) are the primary
regulators of T cell responses. Whereas CD28 primarily activates T cell processes, CTLA-4 inhibits
them. The mechanism for this dichotomy is not fully understood, especially as CD28 and CTLA-4
recruit similar signalling molecules. In addition, recent studies demonstrate that CD28 and CTLA-4
have multiple functions during T cell responses. In particular, CTLA-4 exerts independent distinct
effects during different phases of T cell responses that could be exploited for the treatment of
rheumatoid arthritis.
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activation of APCs, it is indispensable during the initiation
phase of the immune response, which is demonstrated by
data showing altered immune regulation in CD86
knockout mice [4]. CD80 and CD86 have overlapping
functions [5], despite different binding determinants,
different dissociation kinetics, and different binding
affinities for CD28 and CTLA-4. Differences in their
functions seem to be due to different kinetics of
expression on different cell types. The crystal structures
and an analysis of the binding affinities and kinetics of
CTLA-4 with its ligands suggest that CD86 monomers
bind to CTLA-4 dimers, whereas CD80 dimers bind two
adjacent bivalent CTLA-4 dimers, building a lattice-like
network (Fig. 1) [6–8]. In contrast, CD28 is monovalent
and only able to bind a single CD80 or CD86 molecule.
Interestingly, CTLA-4 has a much higher binding affinity for
CD86 and CD80 than CD28 [9]. At 0.2 µM, the affinity of
the CTLA-4–CD80 interaction is one of the highest
described for surface molecules.
CD28 is constitutively expressed on naive CD4+ T cells
and is slightly upregulated after T cell activation. The
expression of CTLA-4 mRNA is detectable in naive T cells
within 1 hour after activation [10]. After activation of the
T cell, intracellular CTLA-4 protein increases steadily in
concentration and is stored in vesicles. Intracellular
CTLA-4 protein is still detectable after a resting period of
a week [11]. Because CTLA-4 protein can be detected
intracellularly 24–48 hours after the onset of T cell
activation, it has been suggested that the molecule is
probably also expressed on the cell surface of these cells
and is functional. Surface expression of CTLA-4 does not
peak until 48–72 hours after T cell stimulation, and it has
recently been shown that only a fraction of activated T cells
express it on the cell surface [11]. The localization of
CTLA-4 on the cell surface is regulated by the association
of clathrin-coated pit adaptor protein AP-2 with the
intracellular tyrosine-based motif of CTLA-4 (Fig. 1) [12,13].
CTLA-4 molecules are mobilized toward the sites of
Figure 1
CD28 and cytotoxic T-lymphocyte antigen-4 (CTLA-4) recruit similar and distinct signalling molecules. (a) The unphosphorylated CTLA-4 molecule
binds the medium-chain subunit of the clathrin adaptor AP-2. This interaction leads to a rapid internalization of CTLA-4 and tight regulation of
surface CTLA-4. CTLA-4 is also able to bind the serine/threonine phosphatase protein phosphatase 2A (PP2A). PP2A seems to act as a negative
regulator of CTLA-4 function and dissociates from CTLA-4 upon ligand binding. The ligands are the dimeric CD80 and the monomeric CD86.
Binding of CD80 to the divalent CTLA-4 leads to the formation of a lattice-like structure on the cell surface. This pattern formation cannot occur by
the interaction of CD86 with CTLA-4. Activation of CTLA-4 by binding to its ligands leads to the phosphorylation of tyrosine residues in the
cytoplasmic tail of CTLA-4 and its association with phosphoinositide 3-kinase (PI-3K) and (perhaps indirectly) the tyrosine phosphatase SHP-2.
The immediate consequences of these interactions are unclear but eventually lead to an inhibition of T cell activation. This includes decreased raft
recruitment to the plasma membrane, decreased phosphorylation of CD3-ζ and ZAP-70, downregulation of mitogen-activated protein kinases such
as extracellular signal-related kinase and c-Jun N-terminal kinase, and inhibition of the nuclear translocation of the transcription factors AP-1 and
nuclear factor of activated T-cells (NFAT). This results in decreased interleukin (IL)-2 production and cell-cycle arrest. (b) In its unphosphorylated
state CD28 binds the serine/threonine phosphatase PP2A. CD28 shares the same ligands, CD80 and CD86, as CTLA-4. However, because
CD28 is monovalent it is not able to form higher-order structures after interaction with CD80. The tyrosine phosphorylation of CD28 after
stimulation by CD80 or CD86 is followed by the association of PI-3K and Grb-2 to the cytoplasmic tail of CD28. This leads to increased T cell
activation, indicated by enhanced raft expression and upregulated production of IL-2. The increased survival is a consequence of upregulated Bcl-
XL and the activation of nuclear factor (NF)-κB.47
antigen receptor engagement and are probably displayed
at the immunological synapse [14,15].
The highly restricted regulation of CTLA-4 localization in a
cell suggests that the restricted surface expression of
CTLA-4 is a major control point for the regulation of the
inhibitory function of CTLA-4 on T cells. A quantitative
increase in the surface expression of CTLA-4 has been
suggested to correlate with the number of cell cycles [16].
This would imply that the transcription machinery of the
CTLA-4 gene would have the ability to count cell cycles
and convert this information into expression. However,
using a sensitive detection method to detect CTLA-4 on
the surface of activated T cells with a sensitivity of less
than 200 molecules per cell, it can be shown that
expression is independent of the proliferative history of the
cell and is exclusively dependent on the time elapsed
since the onset of activation of the T cell [11]. The expres-
sion of surface CTLA-4 is not correlated with the proliferative
history, nor is proliferation a mandatory prerequisite for
CTLA-4 expression. Furthermore, the instruction for a T cell
to express surface CTLA-4 2 days after the onset of the
activation requires less than 12 hours of T cell stimulation,
implying that the induction of CTLA-4 surface expression
and its function can happen at distinct sites in the body.
This result has major implications for the response of
activated T cells, because the cells that receive the
instruction to express surface CTLA-4 in this time
window will eventually express CTLA-4, with all the
consequences.
Surface CTLA-4 is rarely expressed on activated primary
CD4+ T cells and is expressed at higher frequencies after
restimulation [11], indicating that it is an important
regulator of responses of antigen-experienced T cells. This
was confirmed by comparing the T cell responses of
monospecific CTLA-4–/– and CTLA-4+/+ cells [17]. No
difference between these populations was detectable
during a primary response, but there was enhanced
expansion of CTLA-4–/– T cells in a secondary response.
After initial activation, naive CD4+ cells differentiate into
Th1 and Th2 cells, which secrete distinct sets of
cytokines. Studies on CTLA-4 expression of differentiated
Th1 and Th2 cells have been performed mostly in Th1 and
Th2 long-term T cell clones [18]. With the use of a
conventional detection method, it could be shown that
Th2 clones express surface CTLA-4, whereas the protein
was undetectable on Th1 clones. Hence, the differen-
tiation history of an activated naive T cell apparently
correlates with CTLA-4 surface expression after re-
encountering an antigen. This also implies that mainly
antigen-experienced T cells express surface CTLA-4 and
are probably regulated by it [17–19]. This fact is of
particular interest for already established T cell responses
driven by antigen-experienced T cells as they occur during
chronic immunopathology.
Controlled T cell activation by CD28 and CTLA-4
CD28 and CTLA-4 have distinct functions during T cell
activation. Triggering of CD28 enhances raft accumulation
and the accumulation of transcription factors, such as
AP-1 and nuclear factor of activated T cells (NFAT), in the
nucleus; this strongly upregulates the initiation of
interleukin (IL)-2 transcription [20]. CD28 also enhances
the mRNA stability of cytokine genes, for example IL-2 and
interferon-γ [21], as well as the expression of G1-kinases,
a prerequisite for cell cycling. In addition, the induction of
IL-2 leads to autocrine support for the activation of the cell
cycle machinery; the IL-2 signal induces the degradation
of the cell cycle inhibitor p27 and expression of G1-
kinases, which ultimately leads to T cell proliferation [22].
CTLA-4 seems to be an important downregulator of T cell
activation. As early as 4 hours after the onset of T cell
activation, crosslinking of CTLA-4 by specific antibodies
shows that it is expressed functionally by at least some
T cells and prevents complete T cell activation [22]. The
main effect of CTLA-4 engagement during T cell activation
is probably the inhibition of transcription of the IL-2 gene
by preventing NFAT translocation to the nucleus [22]. This
might just be a consequence of the prevention of T cell
activation in general; nevertheless, CTLA-4 also directly
inhibits the expression of key components of the cell cycle
machinery such as cyclin D3, cyclin-dependent kinase
(Cdk)4, and Cdk6, which are partly IL-2 dependent and
partly upregulated independently. The expression of
activation-induced molecules such as CD69 and CD25 is
also prevented by crosslinking of CTLA-4 [23].
So far, CTLA-4 protein has not been detected on the cell
surface of naive or resting CD4+ T cells. But even small
amounts of CTLA-4 could potentially inhibit T cell activation
when CD80/CD86 molecules are expressed at low levels
because CTLA-4 has a much higher affinity than CD28 for
CD80/CD86 [2]; moreover, it is preferentially localized in
lipid rafts [24]. According to earlier results, CTLA-4 mRNA
was detectable in naive CD4+ T cells [25], but enhanced
surface staining for CTLA-4 performed on naive T cells did
not detect CTLA-4 protein [11]. The surface CTLA-4 is
therefore expressed at very low concentrations (fewer
than 100–200 CTLA-4 molecules per cell) on naive T
cells and functional at this expression level during early T
cell receptor triggering, or surface CTLA-4 is quickly and
shortly upregulated after CD4+ T cell activation, at least
from some cells, which has been reported for other
molecules such as IL-4 [26–30].
Signal transduction of CD28 and CTLA-4
The mechanisms by which CD28 and CTLA-4 transmit
their respective signals are not well understood. Despite
their opposing roles in T cell function, both molecules
share some basic features. It has been shown that not
only do CD28 and CTLA-4 compete for the ligands CD80
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and CD86 [22,23] but both also initiate signalling
pathways. However, both molecules lack intrinsic catalytic
activity in their cytoplasmic tails and they therefore require
association with further signalling molecules. Despite their
opposing functions during T cell responses, CD28 and
CTLA-4 interact with identical signalling molecules: the
phosphoinositide 3-kinase (PI-3K) and the protein
phosphatase 2A (PP2A) (Fig. 1) [31–34]. However, the
functional relevance and consequences of these shared
properties are not well understood.
It is still controversial whether CD28 transmits a unique
signal or only amplifies TCR signals. After engagement of
CD28 by its ligand, tyrosine residues in the cytoplasmic
tail of CD28 become phosphorylated by Src-family
kinases [35], leading to the binding of PI-3K to CD28
[31,32]. Additionally, CD28 triggering induces the
phosphorylation and activation of the kinases Tec and Itk
[36,37] as well as other signalling molecules such as the
guanine-nucleotide-exchange factor Vav-1 or phospho-
lipase Cγ1 [38]. All of these molecules are also activated
by TCR signalling, so CD28 might only be an amplifier. A
unique signal could arise from the dependence of full
phospholipase Cγ1 activation on a signal provided by
CD28 that involves PI-3K, Vav-1, and the adapter
molecule SLP-76 [39].
In another model, CD28 sets the threshold for T cell
activation and amplifies the TCR signal by enhancing the
recruitment of lipid rafts to the plasma membrane [40,41].
In resting/naive cells, lipid rafts are stored in intracellular
vesicles and are redistributed to the plasma membrane
after stimulation. This redistribution is strongly enhanced
by CD28 and facilitates the full signal leading to T cell
activation. However, the signal required for raft
relocalization is unknown at present.
Indications for both the quantitative and the qualitative
signal mediated by CD28 can be derived from the analysis
of gene expression after stimulation with TCR alone,
CD28 alone, or a combination of TCR and CD28 [42].
This study shows that CD28 acts primarily as a signal
amplifier of TCR signalling but also leads to the activation
of a few, though important, distinct genes (such as CD69
and tumor necrosis factor).
Like CD28, CTLA-4 becomes phosphorylated on tyrosine
residues after stimulation, which is mediated by Src-family
kinases, JAK-2 or Rlk [43–45]. The tyrosine residue is
located within a YVKM motif and this has been shown to
serve as the binding site for several molecules (Fig. 1). In
its unphosphorylated state this motif is bound to the
medium-chain subunit AP-50 of the AP-2 clathrin adapter
[12,13], leading to the rapid endocytosis of CTLA-4. In
contrast, tyrosine phosphorylation results in the surface
retention of CTLA-4 and the binding of PI-3K to the YVKM
motif [33]. It has been also described that CTLA-4 can be
found in a complex together with CD3ζ and the tyrosine
phosphatase SHP-2 [46–48]. The direct interaction
between SHP-2 and the signalling molecule CD3ζ is
thought to be a mechanism by which CTLA-4
downregulates TCR signalling. This could also explain the
observation that CD3ζ is hyperphosphorylated in CTLA-4
knockout mice [46]. However, the crosslinking of CTLA-4
in combination with TCR and CD28 did not lead to a
decreased phosphorylation of CD3ζ [49]. In addition, our
own results, gained by the retroviral transduction of
SHP-2 mutants into primary T cells, do not support the
idea of a prominent contribution of SHP-2 in CTLA-4
signalling (H Hoff and MC Brunner-Weinzierl, unpublished
observation).
A second phosphatase that has been shown to interact
with CTLA-4 is the serine/threonine phosphatase PP2A
[34,50]. Because PP2A has been described as a
negative regulator for the mitogen-activated protein
kinases extracellular signal-related kinase and c-Jun N-
terminal kinase, and these molecules are downregulated
after CTLA-4 engagement [49], PP2A might serve as the
mediator for these downstream effects of CTLA-4.
However, so far only the opposite role for PP2A as a
negative regulator for CTLA-4 function has been
described [50].
CTLA-4 is also able to interfere with raft recruitment to the
plasma membrane. It has been shown that CTLA-4 can be
found in lipid rafts [24] and is able to suppress raft
aggregation mediated by TCR and CD28 [51]. This
mechanism would account for a general downregulation
of early T cell activation events by CTLA-4, such as a lack
of NFAT translocation to the nucleus and IL-2 gene
transcription but would dismiss further downstream specific
CTLA-4 signals [22,42]. The nature of this specific signal
is still unknown. Further studies should seek to analyze the
integration of the CTLA-4 signal into the cell signalling
machinery [11] on cells that have already formed rafts. We
have recently reported that already upregulated
molecules such as the α-chain of the IL-2 receptor
cannot be downregulated by CTLA-4 on activated T cells
[11], suggesting that the gene transcription of activated T
cells, rather than the regulation of proteins, is altered by
CTLA-4.
It is not yet clear whether CTLA-4 interferes with CD28
costimulation or with TCR stimulation. Most probably it
interferes with both via the inhibition of raft accumulation,
because it inhibits TCR-mediated effects such as the
upregulation of cyclin-dependent kinases and CD28-
mediated effects such as enhanced accumulation of NFAT
in the nucleus [22]. However, the engagement of CTLA-4
does not interfere with the CD28-mediated stabilization of
IL-2 mRNA [22].
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Responses of already activated T cells
The control of T cells after a successful stimulation –
whereby T cells accumulate rafts at the cell surface,
produce growth factors such as IL-2, and proliferate – is
still a matter of debate. CD28 does not exclusively provide
costimulatory function on already activated T cells,
because activated T cells also express other costimulatory
molecules such as ICOS. However, constitutively
expressed CD28 on T cells is needed to prolong T cell
responses. This is indicated by data from CD28 knockout
mice [52] in which immunization can initiate, but not
sustain, T cell responses.
Detectable CTLA-4 surface expression does not peak until
48–72 hours after the onset of T cell activation, when it
probably exerts its main function. Most studies indicate
that triggering of CTLA-4 downregulates the proliferation
and cytokine production of the entire T cell population, but
this conclusion is probably due to difficulties in detecting
surface-expressed CTLA-4 [22,23,47,53–55]. Applying a
highly sensitive detection method for surface molecules,
we showed recently that at all time points after the onset
of an antigen-specific T cell response, CTLA-4 expression
was limited to a minority of activated cells with a maximum
frequency of surface CTLA-4+ T cells at 48 hours [11]. It
has been shown that CTLA-4 expression needs TCR
signaling and is synergistically enhanced by CD28 and
IL-2 signals, which are undoubtedly stochastic
components of the strength of activation of T cells likely to
be involved [14,56]. In addition, Allison’s group has shown
by microscopy that CTLA-4 traffics differentially to the
immunological synapse depending on the strength of the
signal [15], suggesting that CTLA-4 inhibits some T cell
clones with a high-affinity TCR by decreasing their
competitive advantage over clones with a low-affinity TCR
[57]. Preferential inhibition of T cells with a high-affinity
TCR would prevent these clones from dominating the
response during early stages and would thereby help to
maintain the diversity of antigen-specific cells.
The functional consequence of the heterogeneous surface
expression of CTLA-4 was demonstrated only recently
when highly activated proliferating T cell populations were
separated on the basis of surface CTLA-4 expression and
restimulated [11]. The CTLA-4-expressing cells did not
divide at all, whereas all CTLA-4– cells went through at
least one more cell cycle. The inhibition of proliferation
was mediated by CTLA-4 engagement during restimulation
of the CTLA-4+ T cells as shown by CTLA-4 blockade
with specific Fab fragments. No difference in the
proliferative response was seen when CTLA-4 was
blocked in isolated restimulated CTLA-4– T cells. Thus,
the diversity of clonal T cell proliferation is mediated by the
differential expression of CTLA-4 on the cell surface of
activated individual T lymphocytes. This raises the
possibility that surface CTLA-4-expressing cells might also
have heterogeneous fates. It will be important to determine
whether the surface expression of CTLA-4 restricts only
the expansion of T cells that receive a strong signal or
whether surface CTLA-4-expressing cells represent a
distinct pool of memory T cells [11,15].
Control of apoptosis by CD28 and CTLA-4
The decision between the survival and apoptosis of T cells
is of particular importance for adaptive immune responses
to ensure that a defined number of specialized T cells
remain in the organism, thus maintaining memory and
homeostasis. The primary form of apoptosis of clonally
expanded T cells is activation-induced cell death (AICD),
which is controlled mainly by the Fas (CD95) system
[58,59]. Despite the apparently opposing roles of CD28
and CTLA-4 on T cell functions, synergistic signal trans-
duction is still a possibility because of their similar recruit-
ment of signalling molecules such as PI-3K as described
above [33]. PI-3K is an important signalling node for
activating survival pathways via Akt activation [60,61].
CD28-mediated inhibition of AICD has been associated
with the upregulation of cellular FLICE-inhibitory protein
(c-FLIP) and Bcl-xL and with the inhibition of FasL
expression [62]. Because the upregulation of apoptosis-
inducing molecules is activation dependent, CTLA-4
crosslinking during T cell activation prevents T cell
activation rather than terminating AICD. Thus, these
unactivated or incompletely activated T cells are not prone
to AICD and do not upregulate FasL [63].
CTLA-4 ligation in previously activated concanavalin
A-induced blasts or anti-CD3-stimulated T cells has been
suggested to induce apoptosis, thus terminating the T cell
response [16,64]. This would mean that activated T cells
are stopped by CTLA-4 from proliferating just to be
eliminated by apoptosis, which would happen anyway by
AICD. We observed that resistance to AICD is mediated
by CTLA-4 on already activated Th cells. This CTLA-4-
induced resistance is dependent on the suppression of
the Fas system and is mediated by PI-3K [65]. This activity
of CTLA-4 could explain the observation that Rag2-
deficient mice reconstituted with a mixture of CTLA-4+/+
and CTLA-4–/– T cells do not show enhanced, but rather
decreased, total numbers of lymphocytes after infection
with lymphocytic choriomeningitis virus and Leishmania
major [66]. This surprising observation indicates that
CTLA-4 affects T cell survival not only in a non-
autonomous fashion but eventually also by modulating the
expression of a proapoptotic factor [66].
Indirect inhibitory effects of CTLA-4
The CTLA-4 knockout mouse shows a dramatic pheno-
type [2,54]. It develops a lymphoproliferative disease and
dies at 4–5 weeks of age. But bone marrow chimeras
derived from CTLA-4+/+ and CTLA-4–/– cells do not show
the lymphoproliferative disorder known from CTLA-4
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knockout mice, suggesting that CTLA-4-mediated inhibition
is at least not only cell autonomous [67]. Non-autonomous
indirect effects of CTLA-4 have been suggested, such as
the possibility that tolerance induction by CTLA-4 might
actually work via the APC. CTLA-4 crosslinking of its
ligands CD80/CD86 on the surface of dendritic cells
makes them the principal mediator of inhibition [68].
Ligation of CD80/CD86 induces the production of indole-
amine 2,3-dioxygenase, which breaks down tryptophan.
The absence of tryptophan mediates the downregulation
of T cell activation. This mechanism is not completely
understood; for example, interferon-γ is obligatory for its
induction, which would mean that any Th1 response could
initiate similar effects. Indirect inhibitory effects have been
described involving the induction of transforming growth
factor-β expression by CTLA-4; this has not been
confirmed by others [69,70].
Other indirect inhibitory effects mediated by CTLA-4 are
attributed to Treg cells, which express large amounts of
intracellular CTLA-4 concomitantly with CD25 and show
prolonged surface expression of CTLA-4 after activation
[71]. It is still controversial whether CTLA-4 is needed for
Treg cell effector function. On the one hand, CTLA-4–/– Treg
cells are able to downregulate the activation of target
cells; on the other, blockade of CTLA-4 abrogates the
inhibitory function of Treg cells [72]. Interestingly, naive
T cells, converted to Treg cells by retroviral transduction
with the transcription factor FoxP3, show high expression
of CTLA-4 [73]. Because CD25 is apparently only a
surrogate marker for Treg cells, and the transcription
marker FoxP3 is expressed only intracellularly, prolonged
expression of surface CTLA-4 could be a good marker for
identifying Treg cells viable for the autologous cell therapy
of chronic inflammations.
Polymorphisms of CTLA-4 in rheumatoid
arthritis (RA) and other autoimmune diseases
The human CD28 and CTLA-4 genes map to chromo-
some 2q33 and are separated by about 60 kilobases. The
homologies between CD28 and CTLA-4 strongly suggest
that both genes arose by gene duplication. High
evolutionary pressure, especially on the CTLA-4 gene, is
demonstrated by comparing human and mouse sequences:
the homology of the DNA sequence is 78%, and that of
the protein sequence is 74%. Nevertheless, four poly-
morphisms of the CTLA-4 gene have been identified in
humans. There is a C→T transition at position –318 of the
promoter sequence and a G→A transition at position +49
of exon 1, resulting in an alanine to threonine amino acid
substitution in codon 17 of the leader peptide. A third
polymorphism is a dinucleotide repeat of about 7–32 ATs
in exon 3, and a fourth has been mapped to the 3′
untranslated region of the CTLA-4 gene. All four
polymorphisms have been investigated for linkage with
autoimmune diseases.
The functional consequences have been described for
some of these polymorphisms. For example, T cells from
people carrying the G allele at position +49 showed
increased proliferation in combination with a lower
expression of CTLA-4 on T cells [74,75], whereas people
carrying the protective A allele of the CTLA-4 gene have an
increased expression of CTLA-4 on T cells and decreased
proliferative capacity [76]. This suggests that carrying the
susceptible G allele of CTLA-4 will result in a loss of
peripheral tolerance, leading to autoimmune pathology.
The studies analyzing the possible association between a
CTLA-4 polymorphism and an autoimmune disease vary
greatly in their outcome. In type 1 diabetes, most studies
indicate that the occurrence of the G allele in position +49
constitutes a risk factor, whereas the AA genotype is
protective [77–80]. This linkage to disease was found in
Italian, Romanian, Chinese, and German people. In
contrast, others did not find a linkage between CTLA-4
polymorphisms and type 1 diabetes in French and Czech
populations [81,82]. For multiple sclerosis, most studies
showed no indication for a contribution of CTLA-4 poly-
morphisms at positions –318 and +49 as a disease risk
factor in Canadian, Polish, Finnish, and Dutch populations
[83–86], whereas others found an association between
the G allele of the CTLA-4 gene at position +49 and the
severity of multiple sclerosis in Swedish and German
patients [87,88].
A recent study in mice identified a disease-susceptibility
polymorphism of the CTLA-4 gene affecting CTLA-4 splicing
in exon 2. An A→G transition leads to the skipping of exon 2,
resulting in an increase in the expression of a ligand-
independent isoform of CTLA-4 [89]. In humans, a new
CTLA-4 polymorphism was found in the 3′ untranslated
region 2 kilobases upstream of the stop codon of CTLA-4
[88]. An A→G transition is associated with autoimmune
diseases such as Grave’s disease, type 1 diabetes, and
autoimmune hypothyroidism [89]. This polymorphism of
the CTLA-4 gene affects the splicing of CTLA-4 mRNA;
interestingly, this results in a lower expression of the
soluble form of CTLA-4 mRNA. The authors of the study
speculate that a reduced interaction of B7 and soluble
CTLA-4 might lead to enhanced T cell stimulation. However,
the functional consequences of these findings are still
unknown.
The contribution of CTLA-4 polymorphisms to the risk of
developing RA is still controversial. Whereas some
studies show no association of the CTLA-4 polymorphism
in people from Spain, the UK, and Korea [90–92], others
show CTLA-4 as a disease risk factor in Spanish and
Chinese populations [93–95]. More detailed studies
combining the CTLA-4 polymorphisms with the HLA
genotype of patients found a correlation between the G
allele of CTLA-4 (+49) and the HLA genotype HLA-DRB1,
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known to be a susceptibility gene for RA [96–99]. This
correlation was found in German, Japanese, French,
Italian, and Portuguese populations. This finding stresses
the point that the inheritance of autoimmune diseases are
most probably due to multiple susceptible genes and also
to environmental factors. Thus, minor susceptibility loci are
difficult to identify but still modify risk.
The multiple-function model
Taken together, the new insights into the functional
consequences of CTLA-4 engagement allow the proposal
of a new model of three distinct functions of CTLA-4 that
might be relevant under different circumstances (Fig. 2).
First, CTLA-4 sets the threshold for T cell activation, and
thus probably contributes to maintenance of peripheral
tolerance [100]. However, the observation that the
expression of surface CTLA-4 after the activation of T cells
is detectable on proliferating cells with an activated
phenotype indicates that during an optimal T cell response
the CTLA-4-mediated inhibition of early T cell activation is
dispensable [11]. Second, whereas only a fraction of
activated T cells express CTLA-4 at the cell surface,
CTLA-4 has additional functions in already activated T cells:
(1) to restrain T cell proliferation and (2) to initiate the
survival of T cells. Cells that express a CTLA-4 signal will
be inhibited in their proliferation and survive, whereas cells
that do not express CTLA-4 will exhibit a brief spurt of
enhanced proliferation to eliminate foreign pathogens and
will then die, ensuring that the response is stopped. A
fraction of surviving cells at the end of the immune
response are potential progenitors for memory cells.
Blockade of CD28 and CTLA-4 ligands by
CTLA-4Ig during chronic immune responses
CTLA-4Ig is constructed by genetically fusing the external
domain of human CTLA-4 to the heavy-chain constant
region of human IgG1. CTLA-4Ig binds CD80 and CD86
on APCs, interfering with B7/CTLA-4 and B7/CD28
ligation. In collagen-induced arthritis in rats, CTLA4Ig has
prevented disease induction via a blockade of co-
stimulation by CD28 during T cell activation [101].
However, the prevention of T cell activation by CTLA-4Ig
is not complete, as shown by the finding that co-
administration of CTLA-4Ig with adoptively transferred
TCRtg T cells into primary immunized mice resulted in
reduced, but not completely abolished, expansion of
antigen-specific T cells [102]. However, the prevention of
CD28 signals could also block the activation of beneficial
T cells, which has been suggested for transplantation
[103]. Administration of CTLA-4Ig at the time of trans-
plantation enhances transplant rejection, presumably by
preventing the induction of regulatory T cells. In addition,
the function of CTLA-4Ig is very probably more complex
when administered during continuing responses, because
such responses consist of several individual T cell
responses at different stages running simultaneously (Fig. 2).
In addition, the ligands for both receptors, CD28 and
CTLA-4, are blocked by CTLA-4Ig, thus leaving different
distinct differentiation processes and effector functions of
newly recruited and activated T cells uncontrolled.
During chronic inflammation, the stimulation of antigen-
experienced T cells is, at least partly, independent of
CD28 signalling, putting CTLA-4/CD80 and CTLA-4/
CD86 into the spotlight of the CTLA-4Ig treatment.
Furthermore, it has been shown that CD28– T cells, which
upregulate CTLA-4, contribute to the immunopathology of
RA or might even drive it [104]. Blocking CD28 and
CTLA-4 signals could lead to either enhanced apoptosis
by reduced CD28 and CTLA-4 signals or enhanced
expansion and thus more cytokine production by reduced
CTLA-4 signals. However, we feel that under some
circumstances the T cell proliferation of activated CTLA-4–/–
T cells in vitro is overemphasized, because no difference
in proliferation could be detected in bone marrow chimeras
generated from a mixture of wild-type and CTLA-4–/– cells
[66,67]. Thus, the third function of CTLA-4 that we
propose here, namely the control of survival and apop-
tosis, might be more relevant [65,66]. This mechanism
Available online http://arthritis-research.com/content/6/2/45
Figure 2
Multiple-function model for cytotoxic T-lymphocyte antigen-4 (CTLA-4).
The traditional view of the function of CTLA-4 is that it is upregulated
upon stimulation of the T cells and attenuates the response (top). The
newly proposed model puts together new insights into CTLA-4
functions (bottom). (1) During suboptimal T cell activation, CTLA-4
sets the threshold for activation. (2) Already activated T cells are
inhibited in their proliferation by CTLA-4. (3) CTLA-4 signalling
enhances PI-3K function, triggering cell-autonomous survival signals in
already activated T cells. Surviving cells at the end of an immune
response could be prone to differentiation into memory cells.52
could contribute to the success of the treatment of RA
patients with CTLA-4Ig (see below).
However, whatever mechanisms are acting during the
CTLA-4Ig treatment of RA, a recent double-blind study on
339 RA patients receiving treatment with 10 mg/kg CTLA4Ig
concomitant with methotrexane showed significant
improvement over the placebo group from month 2 to
month 6 [105]. Only a very slight increase in infections
was observed in comparison with methotrexate alone, but
health-related quality of life and both clinical and
laboratory markers of disease activity were significantly
improved. The significance of the finding that two patients
developed seroconversion for CTLA-4-specific antibodies
means that autoimmunity needs to be further investigated.
Conclusion
In several studies, the use of CTLA-4Ig to treat patients
with RA and other inflammatory diseases was shown to be
successful, pinpointing T cells and their costimulation as
an important target for therapy. However, the precise
mechanism is not yet fully understood, because co-
stimulation is very complex. The precise function of distinct
costimulatory molecules depends on the differentiation
and activation status of the T cells as well as the immuno-
logical microenvironment. Thus, a better understanding of
costimulation is of great importance and might lead to
even more specific strategies for novel immunotherapy of
RA and other autoimmune diseases.
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